Rating Rationale
July 01, 2020 | Mumbai
Marc Laboratories Limited
Rating migrated to 'CRISIL BBB-/Stable'
 
Rating Action
Total Bank Loan Facilities Rated Rs.27 Crore
Long Term Rating CRISIL BBB-/Stable (Migrated from 'CRISIL BB+/Stable ISSUER NOT COOPERATING'*)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
*Issuer did not cooperate; based on best-available information
Detailed Rationale

Due to inadequate information, CRISIL, in-line with the Securities and Exchange Board of India guidelines, had migrated the rating of Marc Laboratories Ltd (MLL) to 'CRISIL BB+/Stable Issuer Not Cooperating'. However, the management has subsequently started sharing information, necessary for carrying out a comprehensive review of the rating.  Consequently, CRISIL is migrating the rating on the long-term facilities from 'CRISIL BB+/Stable Issuer not cooperating' to 'CRISIL BBB-/Stable'.
 
The rating reflects the company's established presence in the pharmaceuticals industry backed by the extensive experience of its promoters and presence of own brands. The rating also factors in a comfortable financial risk profile. These strengths are partially offset by the moderate scale of-and working-capital intensive operations.

Key Rating Drivers & Detailed Description
Strengths
* Established market presence: The promoters' experience of over three decades, their in-depth understanding of industry dynamics and healthy relationship with customers and suppliers should continue to support the business. The company has an established market presence backed by its strong pan India distribution and marketing network and products in a broad range of therapeutic segments'with over 700 products and around 800 brands. Though business growth over the medium term might remain impinged on account of Covid-19 related challenges, MLL's business risk profile will continue to be supported by the its strong market presence.
 
* Comfortable financial risk profile: Gearing has remained healthy at below 1 time over the past few fiscals. Though extended credit from suppliers has led to a slightly high total outside liabilities to tangible networth ratio (estimated at 1.4 times as on March 31, 2020), the absence of debt-funded capital expenditure (capex) shall improve the capital structure over the medium term. Also, debt protection metrics remain comfortable.
 
Weaknesses
* Moderate scale of operations: Growth in revenue, estimated at Rs 101 crore during fiscal 2020, has remained muted over the past couple of fiscals. Though consistent demand from established customer base, augmented by orders from state drug corporations and other medical institutions supported the revenue profile, low order book from them hampered growth. Further, covid-19 related issue might continue to constrain scalability over the medium term.
 
* Large working capital requirements: Gross current assets are estimated at a sizeable 332 days as on March 31, 2020 (299 days a year ago). As products manufactured are marketed under own brands, extended credit support of 3-4 months needs to be offered to customers to combat competition. Further, inventory holding remains high at 4-5 months on account of bulk procurement of raw material to garner benefit of lower prices. However, sizeable payables support working capital.
Liquidity Adequate

Cash accrual, expected at Rs 5-7 crore annually should comfortably cover yearly debt obligation of Rs 1.5-1.7 crore and support liquidity. In the wake of large working capital requirements, bank lines were utilised 82% on average over the 11 months through May 2020. Also, the proposed enhancement in limits by Rs 4-5 crore and no sizeable capex plan shall continue aid liquidity over the medium term

Outlook: Stable

CRISIL believes MLL will continue to benefit from its established presence in the industry and a comfortable financial risk profile.
 
Rating sensitivity factors
Upward factors
* Improvement in revenue and profitability leading to annual cash accrual of Rs 10 crore or more
* Efficient working capital management leading to GCAs of less than 200 days
 
Downward factors
* Decline in revenue or profitability leading to cash accrual of Rs 4.5 crore or less
* Stretch in working capital cycle, or sizeable debt-funded capex weakens the financial risk profile

About the Company

Incorporated in 1986, MLL is promoted by Mr Prem Kishore Rastogi and Dr B K Srivastava. The company manufactures and markets pharmaceutical formulations catering to a broad range of therapeutic segments such as orthopedic, gynecology, cardiovascular, gastro-intestinal, and analgesic. The company's head office is in Lucknow, Uttar Pradesh. It has a manufacturing facility each at Baddi (Himachal Pradesh) and Gurugram (Haryana).

Key Financial Indicators
As on / for the period ended March 31   2020* 2019
Operating income Rs crore 101.02 100.22
Reported profit after tax Rs crore 5.05 5.60
PAT margin % 5.00 5.58
Adjusted debt/Adjusted networth Times 0.62 0.59
Interest coverage Times 3.13 3.72
*Provisional

Status of non cooperation with previous CRA
MLL has not cooperated with ICRA Limited (ICRA) which has classified it as non-cooperative vide releases dated Oct 26, 2018 and Sep 19, 2019. The reason provided by ICRA is non-furnishing of information for monitoring of ratings.

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
Rate (%)
Maturity date Issue size (Rs crore) Complexity level Rating assigned with outlook
NA Cash credit NA NA NA 26.5 NA CRISIL BBB-/Stable
NA Long term loan NA NA Mar-23 0.5 NA CRISIL BBB-/Stable
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  27.00  CRISIL BBB-/Stable  21-05-20  CRISIL BB+/Stable (Issuer Not Cooperating)*  30-03-19  CRISIL BBB-/Stable      26-12-17  CRISIL BBB-/Stable  -- 
All amounts are in Rs.Cr.
*Issuer did not cooperate; based on best-available information
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 26.5 CRISIL BBB-/Stable Cash Credit 21 CRISIL BB+/Stable/Issuer Not Cooperating
Long Term Loan .5 CRISIL BBB-/Stable Long Term Loan 6 CRISIL BB+/Stable/Issuer Not Cooperating
Total 27 -- Total 27 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Approach to Recognising Default

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Gaurav Arora
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4536
Gaurav.Arora@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL